


Reduction-Sensitive Dual Functional Nanomicelles for Improved Delivery of Paclitaxel

Xiaolan Zhang,^{†,‡,§} Ke Liu,^{†,‡} Yixian Huang,^{†,‡,§} Jieni Xu,^{†,‡,§} Jiang Li,^{†,‡,§} Xiaochao Ma,^{†,‡} and Song Li^{*,†,‡,§}

[†]Center for Pharmacogenetics, [‡]Department of Pharmaceutical Sciences, School of Pharmacy; [§]University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States

Supporting Information

ABSTRACT: We have developed a dual-functional nanocarrier composed of a hydrophilic polyethylene glycol (PEG) and a hydrophobic farnesylthiosalicylate (FTS, a nontoxic Ras antagonist), which is effective in delivery of hydrophobic anticancer drug, paclitaxel (PTX). To facilitate the retention of the therapeutic activity of the carrier, FTS was coupled to PEG via a reduction-sensitive disulfide linkage (PEG_{5K}-S-S-FTS₂). PEG_{5K}-S-S-FTS₂ conjugate formed uniform micelles with very small size (~30 nm) and the hydrophobic drug PTX could be readily incorporated into the micelles. Interestingly, inclusion of a disulfide linkage into the PEG_{5K}-FTS₂ micellar system resulted in a 4-fold decrease in the critical micelle concentration (CMC). In addition, the PTX loading capacity and colloidal stability of PTX-loaded micelles were improved. HPLC-MS showed that parent FTS could be more effectively released from PEG_{5K}-S-S-FTS₂ conjugate in tumor cells/tissues compared to PEG_{5K}-FTS₂ conjugate *in vitro* and *in vivo*. PEG_{5K}-S-S-FTS₂ exhibited a higher level of cytotoxicity toward tumor cells than PEG_{5K}-FTS₂ without a disulfide linkage. Furthermore, PTX-loaded PEG_{5K}-S-S-FTS₂ micelles were more effective in inhibiting the proliferation of cultured tumor cells compared to Taxol and PTX loaded in PEG_{5K}-FTS₂ micelles. More importantly, PTX-loaded PEG_{5K}-S-S-FTS₂ micelles demonstrated superior antitumor activity compared to Taxol and PTX formulated in PEG_{5K}-FTS₂ micelles in an aggressive murine breast cancer model (4T1.2).



INTRODUCTION

Polymeric micelles are an attractive delivery system due to easy preparation, small size (10–100 nm), and the ability to solubilize hydrophobic drugs and accumulate preferentially within tumors.^{1–5} We previously developed a nanocarrier based on polyethylene glycol (PEG)-derivatized farnesylthiosalicylate (FTS).⁶ PEG_{5K}-FTS₂ readily formed micelles (20–30 nm) that were highly efficient in loading hydrophobic anticancer drugs such as paclitaxel (PTX).⁶ More importantly, PTX-loaded PEG_{5K}-FTS₂ micelles achieved enhanced antitumor efficacy compared to Taxol formulation *in vivo*.⁶ Different from most of the existing drug carriers that lack therapeutic effect, PEG_{5K}-FTS₂ itself exhibits antitumor activity.⁶ FTS is a potent and especially nontoxic Ras antagonist.^{7,8} Ras gene mutations can be found in one-third of human cancers, with the highest incidence in adenocarcinomas of the pancreas (90%), colon (50%), and lung (30%) tumors.⁹ FTS can effectively inhibit the growth of many different types of tumors via inhibition of Ras-dependent signaling involved in tumor maintenance and progression.¹⁰ The mechanism involves the dislodgement of Ras from the cell membrane and subsequent degradation of the protein.^{11,12}

As a dual function carrier, the cleavability of the linkage between PEG and FTS in PEG_{5K}-FTS₂ conjugate is critical for its biological activity. In our previous study, we compared the

antitumor activity of a conjugate with a labile ester linkage, PEG_{5K}-FTS₂(L), with that of a similar conjugate with a relatively stable amide linkage, PEG_{5K}-FTS₂(S).⁶ PEG_{5K}-FTS₂(L) alone showed a significantly higher level of cytotoxicity toward tumor cells compared to PEG_{5K}-FTS₂(S), presumably due to a more ready release of FTS from PEG_{5K}-FTS₂(L) inside tumor cells.⁶ In addition, delivery of PTX via PEG_{5K}-FTS₂(L) micelles led to an improved antitumor activity *in vivo* over PTX formulated in PEG_{5K}-FTS₂(S) micelles.⁶

In this study, we propose to incorporate into PEG_{5K}-FTS₂(L) an additional cleavable linkage (disulfide bond) to further facilitate the release of FTS following intracellular delivery to tumor cells. We choose the disulfide linkage because tumor cells have significantly higher concentrations of glutathione (GSH) than those in the extracellular fluids and the disulfide linkage has been widely used to develop a reduction-sensitive delivery system to facilitate drug release at the tumor site.^{13–24} Our data showed that incorporation into PEG_{5K}-FTS₂(L) of a disulfide linkage led to an enhanced release of FTS inside tumor cells, which was associated with an improved cytotoxicity against tumor cells. Interestingly, the conjugate with a disulfide

Received: July 3, 2014

Revised: August 6, 2014

Published: August 8, 2014




Figure 1. Synthesis scheme of PEG_{5K}-S-S-FTS₂ conjugate.

linkage (PEG_{5K}-S-S-FTS₂) exhibited a reduced critical micelle concentration (CMC) in addition to improved drug loading capacity and formulation stability. Finally, paclitaxel (PTX) formulated in PEG_{5K}-S-S-FTS₂ micelles was significantly more effective than the PEG_{5K}-FTS₂(L) formulation in inhibiting the tumor growth in a murine breast cancer model (4T1.2).

RESULTS

Synthesis of PEG_{5K}-S-S-FTS₂ Conjugate. To facilitate the retention of the antitumor activity of FTS, a cleavable disulfide linkage was used to couple FTS to a hydrophilic PEG (PEG_{5K}-S-S-FTS₂). The chemical structure of PEG_{5K}-S-S-FTS₂ is shown in Figure 1. As shown in ¹H NMR spectra (Supporting Information Figure S1), the signals at 3.63 ppm and 7–8 ppm were attributed to the methylene protons located at the terminus of PEG and the benzene ring protons of FTS, respectively. Additionally, the chemical shift of -CH₂-S-S-CH₂- (2.9–3.1 ppm) could be observed, which confirmed the presence of a disulfide linkage (Supporting Information Figure S1). The molecular weight of PEG_{5K}-S-S-FTS₂ was determined by MALDI-TOF mass spectrometry (Supporting Information Figure S2), which is close to the theoretical value of PEG_{5K}-S-S-FTS₂. Both ¹H NMR and MALDI-TOF mass spectra indicated the successful synthesis of PEG_{5K}-S-S-FTS₂ conjugate.

Characterization of PTX-Free and PTX-Loaded PEG_{5K}-S-S-FTS₂ Micelles. PEG_{5K}-S-S-FTS₂ was soluble in aqueous solution and readily self-assembled to form micelles with size around 30 nm (Figure 2A). Figure 2C shows the TEM images of PEG_{5K}-S-S-FTS₂ micelles. Spherical particles of uniform size were observed and the sizes of the particles observed under TEM were consistent with those measured by DLS. Figure 3 shows the CMCs of PEG_{5K}-FTS₂ and PEG_{5K}-S-S-FTS₂ micelles using pyrene as a fluorescence probe. It is interesting to note that incorporation into PEG_{5K}-FTS₂ of a disulfide linkage led to a ~4-fold decrease in CMC. PTX can be readily loaded into PEG_{5K}-S-S-FTS₂ micelles. The spherical shape and size of the micelles were well retained following incorporation of PTX (Figure 2B,D). We then evaluated the loading capacity and stability of PTX-loaded PEG_{5K}-S-S-FTS₂ micelles and compared to those of PEG_{5K}-FTS₂ formulation. As shown in Table




Figure 2. Particle size distribution of PTX-free PEG_{5K}-S-S-FTS₂ (A), and PTX-loaded PEG_{5K}-S-S-FTS₂ micelles (B). TEM images of PTX-free PEG_{5K}-S-S-FTS₂ (C), and PTX-loaded PEG_{5K}-S-S-FTS₂ micelles (D).

1, PTX could be loaded in PEG_{5K}-S-S-FTS₂ micelles at a carrier/drug molar ratio as low as 1/1. In contrast, a minimal carrier/drug molar ratio of 2.5/1 was needed to formulate PTX in PEG_{5K}-FTS₂ micelles. Increasing the carrier/drug molar ratio was associated with an improvement in both drug loading efficiency (DLE) and the colloidal stability of PTX-loaded micelles (Table 1). In addition, PTX-loaded PEG_{5K}-S-S-FTS₂ micelles showed better colloidal stability than PEG_{5K}-FTS₂ formulation at all carrier/drug ratios examined (Table 1).

In Vitro Cytotoxicity of Drug-Free Micelles. The antitumor activities of two PTX-free micelles, PEG_{5K}-S-S-FTS₂ and PEG_{5K}-FTS₂, were tested in HCT-116 and DU-145 cancer cell lines and compared to free FTS (Figure 4). PEG_{5K}-FTS₂ conjugate with an ester linkage was used as a reduction-insensitive control. As shown in Figure 4A, free FTS inhibited the HCT-116 cell growth in a concentration-dependent manner. PEG_{5K}-FTS₂ with a reduction-insensitive ester linkage was less active than free FTS in cytotoxicity (Figure 4A). Interestingly, incorporation into PEG_{5K}-FTS₂ of an additional disulfide linkage led to a significant improvement in cytotoxicity




Figure 3. Critical micelle concentration (CMC) of PEG_{5K}-S-S-FTS₂ (A) and PEG_{5K}-FTS₂ (B) micelles.

Table 1. Physicochemical Characterization of Free Drug and PTX-Loaded PEG_{5K}-FTS₂ and PEG_{5K}-S-S-FTS₂ Micelles

micelles	molar ratio	conc. of PTX ^a (mg/mL)	size ^b (nm)	PDI ^c	DLC ^d (%)	DLE ^e (%)	stability ^f (h)
PEG _{5K} -FTS ₂	-	-	17.6	0.20	-	-	-
PEG _{5K} -FTS ₂ :PTX	2.5:1	1	24.9	0.35	5.5	81.2	2
PEG _{5K} -FTS ₂ :PTX	5:1	1	25.6	0.23	2.8	97.6	20
PEG _{5K} -S-S-FTS ₂	-	-	32.4	0.21	-	-	-
PEG _{5K} -S-S-FTS ₂ :PTX	1:1	1	28.5	0.22	12	85.2	1
PEG _{5K} -S-S-FTS ₂ :PTX	2.5:1	1	32.0	0.30	5.2	89.7	3.5
PEG _{5K} -S-S-FTS ₂ :PTX	5:1	1	30.2	0.35	2.6	94.8	30

^aPTX concentration in micelle was kept at 1 mg/mL. Blank micelle concentration was 20 mg/mL. Values reported are the mean \pm SD for triplicate samples. ^bMeasured by dynamic light scattering particle size. ^cPDI = polydispersity index. ^dDLC = drug loading capacity. ^eDLE = drug loading efficiency. ^fData means there was no noticeable size change during the follow-up period.




Figure 4. Cytotoxicity of drug free PEG_{5K}-FTS₂ and PEG_{5K}-S-S-FTS₂ micelles in comparison to free FTS in HCT-116 human colon carcinoma cell line (A) and DU-145 human prostate cancer cell line (B). Cells were treated for 72 h and cytotoxicity was determined by MTT assay.




Figure 5. HPLC analysis of the amounts of released free FTS in PC-3 or DU-145 prostate cancer cells 72 h following treatment with PEG_{5K}-S-S-FTS₂ or PEG_{5K}-FTS₂ at a FTS concentration of 20 μ M.

compared to both free FTS and PEG_{5K}-FTS₂ (Figure 4A). A similar result was observed in DU-145 cell line (Figure 4B).

Release of FTS from the PEG_{5K}-S-S-FTS₂ and PEG_{5K}-FTS₂ Conjugates. To investigate whether the improved cytotoxicity of PEG_{5K}-S-S-FTS₂ over PEG_{5K}-FTS₂ is attributed to a more effective release of FTS, HPLC-MS was employed to analyze FTS release inside PC-3 or DU-145 human prostate cancer cells 72 h following treatment with PEG_{5K}-FTS₂ or PEG_{5K}-S-S-FTS₂ micelles. We focused on the detection of the signal of parent FTS. The FTS extraction protocol had minimal impact on the integrity of PEG_{5K}-S-S-FTS₂ as demonstrated in a preliminary study (data not shown). Figure 5A shows that incorporation into PEG_{5K}-FTS₂ a disulfide linkage led to a 2- to 3-fold increase in the amounts of free FTS detected in PC-3 cells (Figure 5A). A similar result was observed in DU-145 cell line (Figure 5B). We also conducted a preliminary study on the release of FTS in tumor tissues *in vivo*. Female BALB/c mice bearing 4T1.2 tumor (~1 cm) received i.v. injection of PEG_{5K}-S-S-FTS₂ and PEG_{5K}-FTS₂ micelles at the same dose and the amounts of free FTS in the tumor tissues were examined 24 h later. As shown in Figure 6, a strong signal of FTS was detected




Figure 6. HPLC-MS analysis of FTS in blood and tumors 24 h following i.v. administration of PEG_{5K}-FTS₂ and PEG_{5K}-S-S-FTS₂.

in the tumor tissues while very little FTS signal was found in the blood. It is also apparent that significantly greater amounts of free FTS were found in the tumors treated with PEG_{5K}-S-S-FTS₂ compared to the PEG_{5K}-FTS₂-treated tumors (Figure 6),

indicating that FTS is more readily cleaved from PEG_{5K}-S-S-FTS₂ micelles at the tumor sites.

In Vitro Cytotoxicity of Drug-Loaded Micelles. Figure 7 shows the *in vitro* cytotoxicity of PTX formulated in PEG_{5K}-FTS₂ or PEG_{5K}-S-S-FTS₂ micelles, in comparison with Taxol formulation in MCF-7 and HCT-116 cells. Taxol inhibited the proliferation of MCF-7 breast cancer cells in a concentration dependent manner (Figure 7A). Delivery of PTX via PEG_{5K}-FTS₂ micelles led to a slight increase in cytotoxicity against MCF-7 tumor cells. More importantly, PTX formulated in PEG_{5K}-S-S-FTS₂ micelles were more active than both Taxol formulation and PTX-loaded PEG_{5K}-FTS₂ micelles in inhibiting the tumor cell growth, particularly at low PTX concentrations (Figure 7A). A similar result was observed in a colon carcinoma cell line, HCT-116 (Figure 7B).

In Vivo Therapeutic Study. Figure 8 shows the *in vivo* therapeutic activity of PTX formulated in PEG_{5K}-S-S-FTS in an aggressive murine breast cancer model (4T1.2). PEG_{5K}-S-S-FTS₂ micelles alone showed no effects in inhibiting the tumor growth at the concentration used. This is due to a relatively low concentration of FTS in this group. Taxol formulation showed a modest tumor growth inhibition at a dose of 10 mg PTX/kg (Figure 8A). In contrast, both PTX-loaded PEG_{5K}-FTS₂ and PEG_{5K}-S-S-FTS₂ micelles were more effective than Taxol formulation at the same dose (Figure 8A). More importantly, PTX formulated in PEG_{5K}-S-S-FTS₂ micelles exhibited even more potent tumor growth inhibition than PTX-loaded PEG_{5K}-FTS₂ micelles ($P < 0.05$) (Figure 8A). No significant changes in body weight were detected in all treatment groups compared to PBS control group (Figure 8B).

DISCUSSION

We have previously reported that PTX-loaded PEG_{5K}-FTS₂(L) micelles showed better antitumor activity than Taxol formulation, which could be ascribed to their preferential tumor accumulation and a possible synergistic effect between PEG_{5K}-FTS₂(L) carrier and loaded PTX.⁶ In this study, we have shown that inclusion of a disulfide linkage led to a further improvement in the therapeutic activity compared to PTX formulated in PEG_{5K}-FTS₂(L) micelles and Taxol *in vivo* (Figure 8).

Similar to PEG_{5K}-FTS₂(L), PEG_{5K}-S-S-FTS₂ readily self-assembled to form micelles in aqueous solution with relatively




Figure 7. Cytotoxicity of PTX-loaded PEG_{5K}-FTS₂ and PEG_{5K}-S-S-FTS₂ micelles in comparison to Taxol formulation in MCF-7 human breast carcinoma cell line (A) and HCT-116 human colon carcinoma cell line (B). Cells were treated for 72 h and cytotoxicity was determined by MTT assay.

molecule intermediate can be effectively hydrolyzed by the intracellular esterases to generate the parent FTS (Figure 9).

In vitro cytotoxicity showed that PEG_{5K}-S-S-FTS₂ conjugate was significantly more effective in inhibiting the proliferation of cultured tumor cells compared to PEG_{5K}-FTS₂(L) conjugate (Figure 4). The increased cytotoxicity of PEG_{5K}-S-S-FTS₂ is most likely due to a facilitated release of FTS following inclusion of an additional cleavable disulfide linkage. It is interesting to note that PEG_{5K}-SS-FTS₂ also exhibited higher levels of cytotoxicity than free FTS at low concentrations (Figure 4). This is unlikely due to the surfactant activity of the conjugate as PEG_{5K}-SS-FTS₂ showed minimal hemolytic activity at even much higher concentrations (data not shown). It is possible that PEG_{5K}-SS-FTS₂ is more effectively taken by tumor cells than free FTS, which will be further examined in the future. PEG_{5K}-S-S-FTS₂ not only retained the biological activity well, but also served as an efficient carrier to deliver hydrophobic drug PTX. PTX formulated in PEG_{5K}-S-S-FTS₂ micelles showed a level of cytotoxicity that was higher than that of either Taxol or PTX formulated in PEG_{5K}-FTS₂(L) micelles (Figure 7), particularly at low PTX concentrations.

In vivo antitumor study showed that PTX formulated in PEG_{5K}-FTS₂(L) micelles were significantly more effective than Taxol formulation in a syngeneic murine breast cancer model (Figure 8), which is consistent with our previous report.⁶ It is also apparent that inclusion of a disulfide linkage in PEG_{5K}-FTS₂(L) micellar system led to a further improvement in antitumor activity (Figure 8). The improved performance is likely attributed to a more effective cleavage of FTS from the conjugate in the tumor tissue, which shall lead to not only enhanced intracellular delivery of FTS but also facilitated release of loaded drug following disassembly of micelles. It remains to be investigated whether the improved carrier/drug interaction and the reduced CMC of the PEG_{5K}-S-S-FTS₂ micellar system also contribute to the overall improvement in antitumor activity.

CONCLUSION

An improved dual-functional micellar carrier composed of a PEG shell and FTS core via a disulfide linkage (PEG_{5K}-S-S-FTS₂) was developed. PEG_{5K}-S-S-FTS₂ retained the FTS biological activity well, which was attributed to an effective release of FTS from the conjugate following intracellular delivery. In addition, PEG_{5K}-S-S-FTS₂ readily self-assembled into small-sized micelles and formed stable mixed micelles with PTX. More importantly, PTX-loaded PEG_{5K}-S-S-FTS₂ micelles demonstrated more effective therapeutic effects *in vivo* over Taxol formulation and PTX-loaded PEG_{5K}-FTS₂ micelles.

EXPERIMENTAL PROCEDURES

Materials. Paclitaxel (98%) was purchased from AK Scientific Inc. (CA, USA). FTS and PEG_{5K}-FTS₂ conjugate were synthesized according to published literature.^{6,7} Poly-(ethylene glycol) methyl ether (MeO-PEG-OH, MW = 5000 kDa), dimethyl sulfoxide (DMSO), succinate anhydride, diethanolamine, trypsin-EDTA solution, Dulbecco's Modified Eagle's Medium (DMEM), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were all purchased from Sigma-Aldrich (MO, USA). Di-Boc-lysine, triethylamine (TEA), and trifluoroacetic acid (TFA) were obtained from Acros Organic (NJ, USA). Bis(2-hydroxyethyl) disulfide, dicyclohexylcarbodiimide (DCC), and *N*-hydroxysuccinimide

(NHS) were purchased from Alfa Aesar (MA, USA). 4-(Dimethylamino)pyridine (DMAP) was purchased from Calbiochem-Novabiochem Corporation (CA, USA). All solvents used in this study were HPLC grade.

Cell Culture. MCF-7 is a human breast carcinoma cell line. 4T1.2 is a mouse metastatic breast cancer cell line. HCT-116 is a human colon carcinoma cell line. PC-3 and DU-145 are human prostate cancer cell lines. All cell lines were cultured in DMEM containing 5% FBS and 1% penicillin–streptomycin at 37 °C in a humidified 5% CO₂ atmosphere.

Animals. Female BALB/c mice, 4–6 weeks in age, were purchased from Charles River (Davis, CA). All animals were housed under pathogen-free conditions according to AAALAC guidelines. All animal-related experiments were performed in full compliance with institutional guidelines and approved by the Animal Use and Care Administrative Advisory Committee at the University of Pittsburgh.

Synthesis of PEG_{5K}-S-S-FTS₂ Conjugate. Figure 1 shows the synthesis route of PEG_{5K}-S-S-FTS₂ conjugate. Synthesis and structural characterizations are detailed below.

Compound 1. Bis(2-hydroxyethyl) disulfide (1.54 g, 10 mmol) was added to a solution of FTS (3.58 g, 10 mmol), DCC (3.09 g, 15 mmol), and DMAP (122 mg, 1 mmol) in CH₂Cl₂ (50 mL). The mixture was stirred at room temperature until TLC showed completion of reaction. The mixture was filtered through cotton and the filtrate was concentrated on a rotary evaporator. The residue was chromatographed (1:4 EtOAc/PE) on silica gel to afford the compound 1 (3.2 g, 6.5 mmol, 65%). ¹H NMR (400 MHz, CDCl₃) δ 7.99–7.97 (m, 1H), 7.45–7.41 (m, 1H), 7.32–7.28 (m, 1H), 7.17–7.13 (m, 1H), 5.36–5.32 (m, 1H), 5.10–5.07 (m, 2H), 4.59 (t, *J* = 6.8 Hz, 2H), 3.88–3.87 (m, 2H), 3.58–3.56 (m, 2H), 3.06 (t, *J* = 6.8 Hz, 2H), 2.89 (t, *J* = 6 Hz, 2H), 2.09–1.97 (m, 8H), 1.73 (s, 3H), 1.68 (s, 3H), 1.60 (s, 6H).

Compound 2. Succinic anhydride (2 g, 20 mmol) was added to a solution of compound 1 (4.94 g, 10 mmol) and DMAP (2.44 g, 20 mmol) in CHCl₃ (50 mL), and the mixture was refluxed until TLC showed completion of reaction. The mixture was concentrated on a rotary evaporator and the residue was chromatographed (1:1 EtOAc/PE) on silica gel to afford the compound 2 (5.8 g, 6.5 mmol, 97%). ¹H NMR (400 MHz, CDCl₃) δ 7.99–7.97 (m, 1H), 7.41–7.38 (m, 1H), 7.29–7.27 (m, 1H), 7.14–7.10 (m, 1H), 5.30–5.27 (m, 1H), 5.06–5.03 (m, 2H), 4.54 (t, *J* = 6.8 Hz, 2H), 4.33 (t, *J* = 6.8 Hz, 2H), 3.55–3.53 (m, 2H), 3.03 (t, *J* = 6.4 Hz, 2H), 2.89 (t, *J* = 6.4 Hz, 2H), 2.62–2.61 (m, 4H), 2.04–1.92 (m, 8H), 1.69 (s, 3H), 1.64 (s, 3H), 1.55 (s, 6H).

Compound 5. Compound 5 was synthesized from compound 3 following a published method.⁶

Compound 6. DCC, DMAP, compound 2, and compound 5 were dissolved in CH₂Cl₂ with a molar ratio of 1:6:3:0.3 and allowed to react overnight at room temperature. The solution was filtered and precipitated in diethyl ether and ethanol twice, respectively. Compound 6 was obtained by further drying under vacuum.

Preparation and Characterization of PTX-Loaded PEG_{5K}-S-S-FTS₂ Micelles. PTX-solubilized PEG_{5K}-S-S-FTS₂ micelles were prepared via a solvent evaporation method following our published protocol.^{6,18} Briefly, PTX (10 mM in chloroform) and PEG_{5K}-S-S-FTS₂ conjugate (10 mM in chloroform) were mixed with various carrier/drug ratios. A film of drug/carrier mixture was formed by removed the organic solvent and the film was further dried under vacuum.

PTX-loaded micelles were formed by adding DPBS to hydrate the thin film followed by gentle vortexing. The PTX loading efficiency was measured by high performance liquid chromatography (HPLC) (Alliance 2695–2998 system) as described previously.⁶ Drug loading capacity (DLC) and drug loading efficiency (DLE) were calculated according to the following equation:

$$\text{DLC}(\%) = [\text{weight of drug used} / (\text{weight of polymer} + \text{drug used})] \times 100\%$$

$$\text{DLE}(\%) = (\text{weight of loaded drug} / \text{weight of input drug}) \times 100\%$$

Morphology, micelle size, and size distribution were assessed by transmission electron microscopy (TEM) and dynamic light scattering (DLS) following our published protocol.⁴ The critical micelle concentration (CMC) of PEG_{5K}-S-S-FTS₂ micelles was determined using pyrene as a fluorescence probe.²⁷

Release of FTS from the PEG_{5K}-S-S-FTS₂ and PEG_{5K}-FTS₂ Conjugates. DU-145 and PC-3 cells were seeded in 6-well plates. After 24 h of incubation in DMEM with 5% FBS, the old medium was removed and the cells were incubated for 72 h in the presence of drug-free PEG_{5K}-S-S-FTS₂ or PEG_{5K}-FTS₂ micelles. The cells were washed with ice-cold PBS three times and solubilized via a mixture of MeOH and H₂O. The lysates were vortexed and then centrifuged at 14 000 rpm for 10 min at 4 °C. Supernatants were transferred to another set of 1.5 mL microtubes and stored at –80 °C for MS analysis. The amount of FTS in each sample was quantified by Waters' SYNAPT G2-S mass spectrometer according to the literature.^{28,29} Chromatographic separation of FTS was performed on an Acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm, Waters). The mobile phase A (MPA) was 0.1% formic acid in acetonitrile, and mobile phase B was 0.1% formic acid in water. The flow rate of mobile phase was 0.40 mL/min and the column temperature was maintained at 50 °C. Data were processed using QuanLynx (v 4.1, Waters). Extracted ion chromatograms (EICs) were extracted using a 20 mDa window centered on the expected *m/z* 357.189 for FTS.

Similarly, FTS release was examined with tumor tissues from female BALB/c mice bearing 4T1.2 tumor (~1 cm). Groups of 4 mice received i.v. injection of PEG_{5K}-FTS₂ or PEG_{5K}-S-S-FTS₂ conjugate at a dose of 58.5 μmol/kg. One day post injection, blood and tumors were collected. Samples were homogenized with PBS, and then mixed with 2 volumes of acetonitrile. The mixture was vortexed for 1 min, incubated for 5 min, and centrifuged at 14 000 rpm for 10 min at 4 °C. The supernatants were decanted from each sample into a clean centrifugation tube for MS analysis and FTS was then analyzed as described above.

In Vitro Cytotoxicity Study. The cytotoxicity of PTX formulated in PEG_{5K}-S-S-FTS₂ micelles was assessed with several cancer cell lines and compared to Taxol and PTX loaded in PEG_{5K}-FTS₂ micelles, respectively. Briefly, MCF-7 cells (5000 cells/well) and HCT-116 cells (1000 cells/well) were seeded in 96-well plates. After incubation in DMEM with 5% FBS and 1% streptomycin–penicillin for 24 h, the old medium was removed and the cells were further incubated for 3 days in the presence of indicated concentrations of PTX formulated in Cremophor/EL, PEG_{5K}-S-S-FTS₂, or PEG_{5K}-FTS₂ micelles. Cell viability was then assessed by MTT assay

following our published literature.⁶ Similarly, the cytotoxicity of drug-free PEG_{5K}-S-S-FTS₂ micelles was examined and compared to free FTS and PEG_{5K}-FTS₂ micelles as described above.

In Vivo Therapeutic Study. An aggressive murine breast cancer model (4T1.2) was used to examine the *in vivo* therapeutic effect of different formulations of PTX. Tumors were induced by inoculation of 4T1.2 cells (1 × 10⁵) in 100 μL PBS at the right flank of female BALB/c mice. After tumors in the mice reached a tumor volume of ~40 mm³, treatments were started and this day was designated as day 1. On the first day, tumor (4T1.2)-bearing mice were randomly divided into five groups (*n* = 5) and administered i.v. with PBS (control), drug-free PEG_{5K}-S-S-FTS₂ micelles, Taxol (10 mg PTX/kg), PTX-loaded PEG_{5K}-FTS₂, and PEG_{5K}-S-S-FTS₂ micelles (10 mg PTX/kg), respectively, on days 1, 3, 6, 8, 10, and 12. Tumor sizes were measured twice a week and tumor volumes were calculated by the formula: $(L \times W^2)/2$, where *L* and *W* represent the longest and shortest in tumor diameters (mm). Each group was compared by relative tumor volume (RTV) (where RTV equals to the tumor volume divided by the initial tumor volume before treatment). The body weights of all mice from each group were measured twice a week.

Statistical Analysis. Data are presented as mean ± standard deviation (SD). Statistical analysis was performed by Student's *t* test for comparison of two groups, and comparisons for multiple groups were made with one-way analysis of variance (ANOVA), followed by Newman-Keuls test if the overall *P* < 0.05. In all statistical analysis, the threshold of significance was defined as *P* < 0.05.

■ ASSOCIATED CONTENT

● Supporting Information

Additional figures as discussed in the text. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Tel: 412-383-7976. Fax: 412-648-1664. E-mail: sol4@pitt.edu.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by NIH grants R01CA174305, R01GM102989, and R21CA173887. We would like to thank Drs. Donna Stolz and Ming Sun for their help with negative EM study. We would like to thank Dr. Raman Venkataramanan and Wenchen Zhao for their help with drug loading efficiency test.

■ REFERENCES

- (1) Bourzac, K. (2012) Nanotechnology: Carrying drugs. *Nature* 491, S58–60.
- (2) Torchilin, V. (2009) Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. *Eur. J. Pharm. Biopharm.* 71, 431–444.
- (3) Zhang, X., Huang, Y., and Li, S. (2014) Nanomicellar carriers for targeted delivery of anticancer agents. *Ther. Delivery* 5, 53–68.
- (4) Zhang, P., Lu, J., Huang, Y., Zhao, W., Zhang, Y., Zhang, X., Li, J., Venkataramanan, R., Gao, X., and Li, S. (2014) Design and evaluation of a PEGylated lipopeptide equipped with drug-interactive motifs as an improved drug carrier. *AAPS J.* 16, 114–124.
- (5) Lu, J., Huang, Y., Zhao, W., Marquez, R. T., Meng, X., Li, J., Gao, X., Venkataramanan, R., Wang, Z., and Li, S. (2013) PEG-derivatized

embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers. *Biomaterials* 34, 1591–1600.

(6) Zhang, X., Lu, J., Huang, Y., Zhao, W., Chen, Y., Li, J., Gao, X., Venkataramanan, R., Sun, M., Stolz, D. B., Zhang, L., and Li, S. (2013) PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel. *Bioconjugate Chem.* 24, 464–472.

(7) Marciano, D., Ben-Baruch, G., Marom, M., Egozi, Y., Haklai, R., and Kloog, Y. (1995) Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. *J. Med. Chem.* 38, 1267–1272.

(8) Haklai, R., Weisz, M. G., Elad, G., Paz, A., Marciano, D., Egozi, Y., Ben-Baruch, G., and Kloog, Y. (1998) Dislodgment and accelerated degradation of Ras. *Biochemistry* 37, 1306–1314.

(9) Bos, J. L. (1989) Ras oncogenes in human cancer: a review. *Cancer Res.* 49, 4682–4689.

(10) Goldberg, L., Haklai, R., Bauer, V., Heiss, A., and Kloog, Y. (2009) New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models. *J. Med. Chem.* 52, 197–205.

(11) Paz, A., Haklai, R., Elad-Sfadia, G., Ballan, E., and Kloog, Y. (2001) Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. *Oncogene* 20, 7486–7493.

(12) Rotblat, B., Ehrlich, M., Haklai, R., and Kloog, Y. (2008) The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. *Methods Enzymol.* 439, 467–489.

(13) McCarley, R. L. (2012) Redox-responsive delivery systems. *Annu. Rev. Anal. Chem.* 5, 391–411.

(14) Saito, G., Swanson, J. A., and Lee, K. D. (2003) Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. *Adv. Drug Delivery Rev.* 55, 199–215.

(15) Meng, F., Hennink, W. E., and Zhong, Z. (2009) Reduction-sensitive polymers and bioconjugates for biomedical applications. *Biomaterials* 30, 2180–2198.

(16) Huang, H., Zhang, X., Yu, J., Zeng, J., Chang, P. R., Xu, H., and Huang, J. (2013) Fabrication and reduction-sensitive behavior of polyion complex nano-micelles based on PEG-conjugated polymer containing disulfide bonds as a potential carrier of anti-tumor paclitaxel. *Colloids Surf., B: Biointerfaces* 110, 59–65.

(17) Wu, G., Fang, Y. Z., Yang, S., Lupton, J. R., and Turner, N. D. (2004) Glutathione metabolism and its implications for health. *J. Nutr.* 134, 489–492.

(18) Duan, K., Zhang, X., Tang, X., Yu, J., Liu, S., Wang, D., Li, Y., and Huang, J. (2010) Fabrication of cationic nanomicelle from chitosan-graft-polycaprolactone as the carrier of 7-ethyl-10-hydroxycamptothecin. *Colloids Surf., B: Biointerfaces* 76, 475–482.

(19) Li, Y., Xiao, K., Luo, J., Xiao, W., Lee, J. S., Gonik, A. M., Kato, J., Dong, T. A., and Lam, K. S. (2011) Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery. *Biomaterials* 32, 6633–6645.

(20) Wang, H., Tang, L., Tu, C., Song, Z., Yin, Q., Yin, L., Zhang, Z., and Cheng, J. (2013) Redox-responsive, core-cross-linked micelles capable of on-demand, concurrent drug release and structure disassembly. *Biomacromolecules* 14, 3706–3712.

(21) Koo, A. N., Min, K. H., Lee, H. J., Lee, S. U., Kim, K., Kwon, I. C., Cho, S. H., Jeong, S. Y., and Lee, S. C. (2012) Tumor accumulation and antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific redox-responsive cross-links. *Biomaterials* 33, 1489–1499.

(22) Lee, S. Y., Tyler, J. Y., Kim, S., Park, K., and Cheng, J. X. (2013) FRET imaging reveals different cellular entry routes of self-assembled and disulfide bonded polymeric micelles. *Mol. Pharmacol.* 10, 3497–3506.

(23) Lee, S. Y., Kim, S., Tyler, J. Y., Park, K., and Cheng, J. X. (2013) Blood-stable, tumor-adaptable disulfide bonded mPEG-(Cys)4-PDLLA micelles for chemotherapy. *Biomaterials* 34, 552–561.

(24) Zhang, M. Z., Ishii, A., Nishiyama, N., Matsumoto, S., Ishii, T., Yamasaki, Y., and Kataoka, K. (2009) PEGylated calcium phosphate nanocomposites as smart environment-sensitive carriers for siRNA delivery. *Adv. Mater.* 21, 3520–3525.

(25) Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., Nishiyama, N., and Kataoka, K. (2011) Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. *Nat. Nanotechnol.* 6, 815–823.

(26) Yokoyama, M. (1992) Block copolymers as drug carriers. *Crit. Rev. Ther. Drug Carrier Syst.* 9, 213–48.

(27) Huang, Y., Lu, J., Gao, X., Li, J., Zhao, W., Sun, M., Stolz, D. B., Venkataramanan, R., Rohan, L. C., and Li, S. (2012) PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel. *Bioconjugate Chem.* 23, 1443–1451.

(28) Haklai, R., Elad-Sfadia, G., Egozi, Y., and Kloog, Y. (2008) Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. *Cancer Chemother. Pharmacol.* 61, 89–96.

(29) Zhao, M., He, P., Xu, L., Hidalgo, M., Laheru, D., and Rudek, M. A. (2008) Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry. *J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.* 869, 142–145.